Review: Pregnane X Receptor Regulates Intestinal Homeostasis in Inflammatory Bowel Disease

Photo by Navy Medicine / Unsplash

Frontiers in Medicine Published May 12, 2026 Medically reviewed May 12, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider that Nr1i2 modulation may influence intestinal inflammation, but evidence is limited to preclinical models.

This narrative review examines the role of the nuclear receptor pregnane X receptor (Nr1i2) in intestinal inflammation, focusing on inflammatory bowel disease. The authors synthesize data from whole-body and tissue-specific Nr1i2-deficient mouse models, as well as knockdown and ligand-based approaches.

Key findings indicate that whole-body Nr1i2 deficiency disrupts intestinal homeostasis and impairs barrier integrity. It also enhances innate immune activation and exacerbates intestinal injury. Conversely, pharmacological activation of Nr1i2 attenuates inflammatory responses and confers protective and restorative effects.

The authors note that the regulation of inflammatory homeostasis by Nr1i2 is context-dependent, which is a key limitation. The review is based on preclinical models, and no human trial data are presented. Sample sizes, effect sizes, and statistical measures are not reported.

For clinicians, these findings suggest that targeting Nr1i2 may represent a potential therapeutic strategy for intestinal inflammatory disorders, but the evidence is preliminary. Further research in human populations is needed before clinical application.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Nuclear receptor subfamily 1 group I member 2 (NR1I2; mouse ortholog Nr1i2), also known as the pregnane X receptor (PXR) or steroid and xenobiotic receptor (SXR), is a ligand-activated transcription factor classically known for its role in xenobiotic metabolism and detoxification. Beyond these canonical functions, accumulating evidence identifies NR1I2 as a key regulator of inflammation and intestinal homeostasis, particularly in inflammatory bowel disease (IBD), where dysregulated inflammatory responses are central to disease pathogenesis and NR1I2 expression is often reduced. In this review, we integrate data from whole-body and tissue-specific Nr1i2-deficient mouse models, as well as knockdown and ligand-based approaches, to define the role of Nr1i2 in intestinal inflammation under basal and pathological conditions. These studies collectively show that whole-body Nr1i2 deficiency disrupts intestinal homeostasis, impairs barrier integrity, and enhances innate immune activation, whereas tissue-restricted deletion, especially within the epithelium, frequently fails to reproduce these phenotypes, underscoring the importance of coordinated Nr1i2 activity across multiple cellular compartments. Across experimental models, most often Nr1i2 deficiency commonly exacerbates intestinal injury, particularly in response to microbial toxins or chemical damage, however attenuated inflammatory responses have been reported in selected metabolic or injury contexts. Conversely, pharmacological activation of Nr1i2 confers protective and restorative effects in a ligand-, tissue-, and context-dependent manner. Together, these findings establish NR1I2 not as a simple anti-inflammatory switch, but as an immune–metabolic integrator that coordinates xenobiotic detoxification, microbial-derived signal sensing, and restraint of innate inflammatory pathways. This review provides a conceptual framework for future studies aimed at elucidating the cell- and context-specific functions of NR1I2 and for guiding the development of targeted therapeutic strategies for intestinal inflammatory disorders.